1073 related articles for article (PubMed ID: 24174327)
21. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
22. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
[TBL] [Abstract][Full Text] [Related]
23. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
[TBL] [Abstract][Full Text] [Related]
24. Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice.
Sachs S; Niu L; Geyer P; Jall S; Kleinert M; Feuchtinger A; Stemmer K; Brielmeier M; Finan B; DiMarchi RD; Tschöp MH; Wewer Albrechtsen N; Mann M; Müller TD; Hofmann SM
Diabetes Obes Metab; 2021 Jan; 23(1):195-207. PubMed ID: 33001570
[TBL] [Abstract][Full Text] [Related]
25. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
26. Incretin hormone mimetics and analogues in diabetes therapeutics.
Green BD; Flatt PR
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):497-516. PubMed ID: 18054732
[TBL] [Abstract][Full Text] [Related]
27. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
28. The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.
Meng Q; Chepurny OG; Leech CA; Pruekprasert N; Molnar ME; Collier JJ; Cooney RN; Holz GG
Diabetes Obes Metab; 2022 Jul; 24(7):1255-1266. PubMed ID: 35293666
[TBL] [Abstract][Full Text] [Related]
29. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Finan B; Yang B; Ottaway N; Smiley DL; Ma T; Clemmensen C; Chabenne J; Zhang L; Habegger KM; Fischer K; Campbell JE; Sandoval D; Seeley RJ; Bleicher K; Uhles S; Riboulet W; Funk J; Hertel C; Belli S; Sebokova E; Conde-Knape K; Konkar A; Drucker DJ; Gelfanov V; Pfluger PT; Müller TD; Perez-Tilve D; DiMarchi RD; Tschöp MH
Nat Med; 2015 Jan; 21(1):27-36. PubMed ID: 25485909
[TBL] [Abstract][Full Text] [Related]
30. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
Conlon JM; O'Harte FPM; Flatt PR
Peptides; 2022 Jan; 147():170706. PubMed ID: 34861327
[TBL] [Abstract][Full Text] [Related]
31. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
32. Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes.
Grespan E; Giorgino T; Natali A; Ferrannini E; Mari A
Metabolism; 2021 Jan; 114():154415. PubMed ID: 33137379
[TBL] [Abstract][Full Text] [Related]
33. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
34. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
Wu Y; Ji T; Lv J; Wang Z
Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
[TBL] [Abstract][Full Text] [Related]
35. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
Tashiro Y; Sato K; Watanabe T; Nohtomi K; Terasaki M; Nagashima M; Hirano T
Peptides; 2014 Apr; 54():19-26. PubMed ID: 24418070
[TBL] [Abstract][Full Text] [Related]
36. An update on peptide-based therapies for type 2 diabetes and obesity.
Bailey CJ; Flatt PR; Conlon JM
Peptides; 2023 Mar; 161():170939. PubMed ID: 36608818
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.
Folli F; Finzi G; Manfrini R; Galli A; Casiraghi F; Centofanti L; Berra C; Fiorina P; Davalli A; La Rosa S; Perego C; Higgins PB
Am J Physiol Endocrinol Metab; 2023 Nov; 325(5):E595-E609. PubMed ID: 37729025
[TBL] [Abstract][Full Text] [Related]
38. Gut hormone polyagonists for the treatment of type 2 diabetes.
Brandt SJ; Götz A; Tschöp MH; Müller TD
Peptides; 2018 Feb; 100():190-201. PubMed ID: 29412819
[TBL] [Abstract][Full Text] [Related]
39. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
40. An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
Ma T; Lu W; Wang Y; Qian P; Tian H; Gao X; Yao W
Eur J Pharmacol; 2022 Jan; 914():174635. PubMed ID: 34800466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]